Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis

Table 1 Studies reporting reactivation of hepatitis B virus in hepatitis B surface antigen -/antibody to hepatitis B core antigen + patients treated with tyrosine kinase inhibitors for hematologic malignancies

Ref.	Type of study	TKI	Overall cohort (n)	HBV-r (n)	HBVr-associated hepatitis (n)	Liver failure
Papatheodoridis et al[2], 2022	Meta-analysis	NS	72	0	0	0
Innocenti et al[3], 2022	Retrospective	Ibrutinib	108	2	0	0
Chiu et al[4], 2023	Retrospective	BTKs	291	2	2	2
Hammond et al[7], 2018	Retrospective	Ibrutinib	21	2	0	0
Tsuruya K et al[8], 2021	Case report	Ibrutinib	/	1	1	0
Lam et al[9], 2023	Case report	Ibrutinib	/	1	1	0

¹Including both past and chronic hepatitis B virus infection.

BTK: Bruton tyrosine kinase; NS: Not specified; TKI: Tyrosine kinase inhibitors; HBV: Hepatitis B virus; HBVr: Hepatitis B virus reactivation.